COVID-19 put mobile digital technology on the fast-track, ushering in a new era of patient connectivity. Capitalizing on this moment will require working through many of the existing hurdles of [….]
The life sciences industry is evolving rapidly into a world where lab experimentation will meet artificial intelligence, automation will merge with human ingenuity and hard-won wisdom, and the power of viral vectors, stem cells, nanotechnology, and gene editing tools will revolutionize health care as we know it.
ROCKVILLE, Md., May 12, 2021 /PRNewswire/ — Emmes (the “Company”), a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation and a portfolio company of Behrman Capital, today announced that it has acquired Orphan Reach, a CRO specialized in clinical research related to rare diseases. Financial terms of the transaction were not disclosed.
The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.
John Newby is the CEO at Virginia Bio, the statewide non-profit trade association for the life science industry. Approximately 300 companies spanning biopharmaceuticals, medical devices, med tech, diagnostics, digital health, bioinformatics, agriculture, and industrial bio and related fields are based in Virginia, mainly clustered around research universities and medical institutions. Virginia Bio is the sole state affiliate and works closely with key national industry organizations BIO, AdvaMed, MDMA, PhRMA and We Work for Health.
The Sixth Annual BioHealth Capital Region Forum brought together industry leaders from across the region who discussed the accomplishments and strengths of the region as its member companies continue to innovate new therapies and medicines in one of the strongest bio-hub regions in the United States.
5 Questions with Stephanie Duatschek, Biopharma Executive Management Consultant “5 Questions With……” is a new BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to [….]
After decades of work, gene therapies promise a revolution in medicine. How can society figure out how to afford them? Join STAT reporters along with selected experts in the field [….]
Learn how we promote biopharmaceutical research and medical innovation to create a strong, vibrant economy and a healthier Maryland. Read more…
Bruce Booth, D.Phil., a partner at Atlas Venture, astutely observed earlier this year that two key resources fueling the growth of biopharma were until recently somewhat geographically spread among the [….]